| Literature DB >> 35589101 |
Mototaro Iwanaga1, Hidemasa Kawamura1, Nobuteru Kubo1, Tatsuji Mizukami1, Takahiro Oike1, Hiro Sato1, Yoshiyuki Miyazawa2, Yoshitaka Sekine2, Reika Kawabata-Iwakawa3, Masahiko Nishiyama3,4, Tatsuya Ohno1, Takashi Nakano1.
Abstract
Castration-resistant prostate cancer shows resistance to not only androgen deprivation therapy (ADT) but also X-ray therapy. On the other hand, carbon ion beams have a high biological effect and are used for various cancers showing resistance to X-ray therapy. The purposes of this study are to clarify the difference in the sensitivity of Castration-resistant prostate cancer to X-ray and carbon ion beams and to elucidate the mechanism. The androgen-insensitive prostate cancer cell line LNCaP-LA established by culturing the androgen-sensitive prostate cancer cell line LNCaP for 2 years in androgen-free medium was used for this study. First, colony formation assays were performed to investigate its sensitivity to X-ray and carbon ion beams. Next, DNA mutation analysis on 409 cancer-related genes and comprehensive transcriptome analysis (RNA-seq) were performed with a next-generation sequencer. Lethal dose 50 values of X-rays for LNCaP and LNCaP-LA were 1.4 Gy and 2.8 Gy, respectively (P < 0.01). The Lethal dose 50 values of carbon ion beams were 0.9 Gy and 0.7 Gy, respectively (P = 0.09). On DNA mutation analysis, AR mutation was observed specifically in LNCaP-LA. From RNA-seq, 181 genes were identified as differentially expressed genes (DEGs; FDR <0.10, P < 0.00076) between LNCaP and LNCaP-LA. Function analysis suggested that cell death was suppressed in LNCaP-LA, and pathway analysis suggested that the NRF2-pathway involved in intracellular oxidative stress prevention was activated in LNCaP-LA. LNCaP-LA showed X-ray resistance compared to LNCaP and sensitivity to carbon ion beams. The AR mutation and the NRF2-pathway were suggested as causes of resistance.Entities:
Keywords: AR; NRF2-pathway; X-ray resistance; carbon ion beam; castration-resistant prostate cancer
Mesh:
Substances:
Year: 2022 PMID: 35589101 PMCID: PMC9303586 DOI: 10.1093/jrr/rrac022
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.438
Fig. 1Result of colony formation assay. (A) LD50 of LNCaP and LNCaP-LA with X-ray irradiation. (B) LD50 of LNCaP and LNCaP-LA with Carbon ion beam irradiation. *P < 0.01.
Fig. 2Heatmap of 181 genes modulated between LNCaP-LA and LNCaP. The heatmap shows gene expression values for LNCaP and LNCaP-LA. Red represents higher expression and blue represents lower expression.
Top 20 pathway [−log(P-value)]
|
|
|
|
|
|
|---|---|---|---|---|
| Glutathione Biosynthesis | 3.70E+00 | 6.67E-01 | NaN | GCLC, GCLM |
| Xenobiotic Metabolism Signaling | 3.38E+00 | 3.31E-02 | NaN | MAPK13, UGT2B28, ALDH3A1, |
| cAMP-mediated signaling | 3.34E+00 | 3.65E-02 | 0 | GNAI1, ADRB2, CNGB3, PDE4D, ADRA2A, NPR3, PDE10A, DUSP4 |
| Cardiomyocyte Differentiation Via BMP Receptors | 3.25E+00 | 1.50E-01 | NaN | BMP2, MEF2C, BMPR1B |
| Serotonin Degradation | 2.65E+00 | 5.97E-02 | NaN | UGT2B17, UGT2B28, ALDH3A1, DHRS2 |
| NRF2-mediated Oxidative Stress Response | 2.43E+00 | 3.33E-02 | 2 | GCLC, DNAJC15, GCLM, FTH1, HMOX1, ENC1 |
| Bile Acid Biosynthesis, Neutral Pathway | 2.31E+00 | 1.54E-01 | NaN | AKR1C3, AKR1C1/AKR1C2 |
| Relaxin Signaling | 2.29E+00 | 3.70E-02 | NaN | GNAI1, GNB4, GUCY1B3, PDE4D, PDE10A |
| G-Protein Coupled Receptor Signaling | 2.28E+00 | 2.73E-02 | NaN | GNAI1, ADRB2, PDE4D, ADRA2A, NPR3, PDE10A, DUSP4 |
| Bladder Cancer Signaling | 2.24E+00 | 4.60E-02 | NaN | FGFR3, DAPK1, FGF13, MMP16 |
| γ-glutamyl Cycle | 2.18E+00 | 1.33E-01 | NaN | GCLC, GCLM |
| Methylglyoxal Degradation III | 2.13E+00 | 1.25E-01 | NaN | AKR1C3, AKR1C1/AKR1C2 |
| Amyloid Processing | 2.07E+00 | 5.88E-02 | NaN | CAPN5, BACE2, MAPK13 |
| Nicotine Degradation III | 2.01E+00 | 5.56E-02 | NaN | CYP1A2, UGT2B17, UGT2B28 |
| Cardiac Hypertrophy Signaling | 1.99E+00 | 2.69E-02 | −0.447 | GNAI1, ADRB2, GNB4, MAPK13, ADRA2A, MEF2C |
| Melatonin Degradation I | 1.94E+00 | 5.26E-02 | NaN | CYP1A2, UGT2B17, UGT2B28 |
| Corticotropin Releasing Hormone Signaling | 1.88E+00 | 3.60E-02 | −1 | GNAI1, GUCY1B3, MAPK13, MEF2C |
| Role of NFAT in Regulation of the Immune Response | 1.87E+00 | 2.92E-02 | NaN | GNAI1, GNB4, HLA-DMB, BLNK, MEF2C |
| Endothelin-1 Signaling | 1.86E+00 | 2.91E-02 | −0.447 | GNAI1, PLA2G16, GUCY1B3, MAPK13, HMOX1 |
| Superpathway of Melatonin Degradation | 1.84E+00 | 4.84E-02 | NaN | CYP1A2, UGT2B17, UGT2B28 |
Top 5 increased and decreased activation z-score in LNCaP-LA
| Diseases or Functions Annotation |
| Activation z-score |
|---|---|---|
| Generation of cells | 5.86E-03 | 3.06 |
| Development of neurons | 4.96E-03 | 2.13 |
| Migration of carcinoma cell lines | 9.91E-04 | 1.97 |
| Differentiation of neurons | 5.66E-03 | 1.67 |
| Proliferation of prostate cancer cell lines | 1.16E-05 | 1.65 |
| Cell death | 5.86E-04 | −1.80 |
| Oxidative stress | 1.89E-03 | −1.97 |
| Apoptosis | 2.38E-04 | −2.01 |
| Organismal death | 1.91E-06 | −2.31 |
| Necrosis | 2.14E-04 | −2.39 |